|Home | Articles | Product Information|
Effects of inositol hexaphosphate on growth and differentiation in K-562 erythroleukemia cell line.
Author(s): Shamsuddin-A-M, Baten-A, Lalwani-N-D.
Source: Cancer letters 1992 Jul 10, VOL: 64 (3), P: 195-202, ISSN: 0304-3835.
Inositol hexaphosphate (InsP6) has recently been shown to inhibit experimental
cancers in vivo. Since the lower phosphorylated forms of InsP6 are important
in cell growth in a wide variety of mammalian cells, we tested the efficacy
of InsP6 in growth reduction of K-562 human erythroleukemia cells in
vitro. We report that InsP6 decreases the K-562 cell population by 19-36%
(P less than 0.001) concomitant to an increased differentiation as evidenced
by ultrastructural morphology and increased hemoglobin synthesis. Pilot
experiments to study the mechanism of action of InsP6 show that following
treatment with InsP6, the concentration of intracellular (Ca2+) ((Ca2+)i)
is increased by 57% (P less than 0.02). Likewise, a 41% increase (P
less than 0.05) in InsP3 and a 26% decrease (P less than 0.02) in InsP2
were noted 1 h following treatment with InsP6. Contrary to the dogma
that cell division is associated with increased (Ca2+)i, our data show
that reduced cell growth and enhanced differentiation is associated
with increased (Ca2+)i and increased InsP3 in the presence of InsP6.
|*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.|